Insider Selling: Illumina (NASDAQ:ILMN) Insider Sells 615 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the transaction, the insider owned 20,953 shares in the company, valued at $3,771,540. This represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

Shares of ILMN stock traded up $2.56 during trading on Thursday, reaching $177.65. The company had a trading volume of 2,913,168 shares, compared to its average volume of 2,004,443. The firm’s 50 day simple moving average is $148.74 and its two-hundred day simple moving average is $137.38. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a one year low of $88.00 and a one year high of $182.84. The company has a market capitalization of $26.88 billion, a PE ratio of 32.30, a PEG ratio of 3.28 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $0.97 earnings per share. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

Several large investors have recently made changes to their positions in ILMN. Pacer Advisors Inc. lifted its position in Illumina by 2.5% during the 1st quarter. Pacer Advisors Inc. now owns 475,235 shares of the life sciences company’s stock valued at $58,577,000 after purchasing an additional 11,602 shares during the period. Glenmede Trust Co. NA lifted its stake in shares of Illumina by 6.5% in the 1st quarter. Glenmede Trust Co. NA now owns 2,288 shares of the life sciences company’s stock valued at $282,000 after purchasing an additional 140 shares during the period. Groupama Asset Managment lifted its stake in shares of Illumina by 3.7% in the 1st quarter. Groupama Asset Managment now owns 9,545 shares of the life sciences company’s stock valued at $1,177,000 after purchasing an additional 340 shares during the period. Janus Henderson Group PLC boosted its position in shares of Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after purchasing an additional 29,094 shares during the last quarter. Finally, Bull Harbor Capital LLC bought a new position in shares of Illumina in the 1st quarter worth $1,413,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday, May 14th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup lifted their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Finally, Guggenheim upped their price target on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $143.56.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.